- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Each year, the AVAC Report frames the most pressing advocacy issues facing the HIV response. At the threshold of 2020, it’s clear that global goals for HIV prevention will miss the mark by a long shot. Though important progress has been made, the crisis UNAIDS called out in 2016 persists today with new infections around 1.7 million annually, a far cry from the 2020 target of fewer than 500,000. So, we asked ourselves, Now What?, and answered with cross-cutting analysis and an advocacy agenda to match.
WHO estimates that 71 million people worldwide were chronically infected with hepatitis C virus (HCV) in 2017. Globally, 23% of new HCV infections and one in three HCV deaths are attributable to injecting drug use (PWID). HCV is also a major concern for people detained in prisons and other closed settings – available data demonstrate that one in four detainees are HCV positive.
This policy brief highlights the current landscape of country hepatitis policies for harm reduction and HCV testing and treatment in PWID and people in prisons. It aims to capture how governments are translating the WHO Global health sector strategy on viral hepatitis, 2016-2021 into national plans, and provides a summary of the enablers and barriers to HCV testing and treatment in these populations.
The Global Fund to Fight AIDS, TB and Malaria has opened up the opportunity to incorporate tobacco control into TB and HIV grants. In line with the 2030 Agenda, the UNDP Strategic Plan 2018-2021, and UNDP’s HIV, Health and Development Strategy 2016-21: Connecting the Dots, UNDP and the Secretariat of the WHO Framework Convention on Tobacco Control (WHO FCTC) have produced this Issue Brief to inform Global Fund applicants on integrating tobacco cessation into Global Fund HIV and TB grants. The Issue Brief outlines how tobacco consumption worsens TB and HIV outcomes and how the integration of tobacco control could increase health benefits and efficiencies. Key approaches and practical options for such integration are outlined, based on a review of research and case studies.
Keywords: TB, HIV, SDGs, response, tobacco
WHO is accountable for reporting back to the World Health Assembly on progress in implementing the Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections based on data received from countries. This report assesses the mid-term progress in 2019 in implementing these global health sector strategies from 2016 to 2021.
The timeliness and availability of the data across the three diseases is limited, being for 2016 or 2017 in most cases. Key data, including 2018 impact data on incidence and mortality, were not available for this report, making it difficult to assess and validate overall trends since the launch of the strategies in 2016.
Keywords: HIV, UHC, STI, hepatitis, diagnosis, treatment, financing
The Annual Report of SAARC TB and HIV/AIDS Centre (STAC) is being presented indicating the programmes, activities and achievements of the year 2017. This is the Twenty-second consecutive comprehensive Annual Report STAC. This report includes a summary of the activities carried out by the Centre for the year 2017 along with introduction, goals, objectives, vision, mission and achievements of the Centre.
The DOH Administrative Order No. 2017-0019 or the Policies and Guidelines in the Conduct of Human Immunodeficiency Virus (HIV) Testing Services (HTS) in Health Facilities defines HIV Treatment hubs as a hospital with an organized HIV and AIDS Core Team (HACT) that facilitates in-patient and out-patient prevention, treatment, care and support services to PLHIV including but not limited to antiretroviral therapy, HIV testing services, clinical management, patient monitoring, and other care and support services.
This paper offers a brief analysis of these two challenges in light of current policies and practices, along with recommendati ons for overcoming them to ensure the implementati on of a drug treatment system that can result in improved health and human rights outcomes for people who use drugs and people dependant on drugs.
This document has been designed to provide a framework to support local and national STI prevalence studies. The aim of these studies is to understand the burden of disease of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT), two priority STIs that can cause adverse birth outcomes. For this, the objective is to epidemiologically describe the prevalence of these two infections among pregnant women and, by proxy, the general population in the country.
This report summarizes the progress in implementing the Global Action Plan achieved during the first year (2017 to 2018) and the remaining challenges, with specific focus on 45 countries accounting for more than 85% of the total burden of HIV infection.
Keywords: HIVDR, prevention, response, surveillance, monitoring
This report presents 2015 data on the consumption of systemic antibiotics from 65 countries and areas, contributing to our understanding of how antibiotics are used in these countries. In addition, the report documents early efforts of the World Health Organization (WHO) and participating countries to monitor antimicrobial consumption, describes the WHO global methodology for data collection, and highlights the challenges and future steps in monitoring antimicrobial consumption.